MAP2K7 and breast cancer: As p70S6K may also be activated by the c-RAF/ERK pathway, we chemically blocked p42/p44MAPK with the U0126 MEK specific inhibitor to further demonstrate the contribution of the c-RAF, ERK, p70S6K pathway in IL-17-induced chemoresistance in breast cancer cell lines.